Elicera Therapeutics AB Logo

Elicera Therapeutics AB

Develops CAR T-cell & oncolytic virus therapies for cancer, enhanced by its iTANK platform.

ELIC | ST

Overview

Corporate Details

ISIN(s):
SE0015382080 (+1 more)
LEI:
549300I35L0R4INBFG27
Country:
Sweden
Address:
C/O Elicera Therapeutics AB, 402 24 Göteborg
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Elicera Therapeutics AB is a clinical-stage immuno-oncology company that develops cell and gene therapies for immune-based cancer treatments. The company's work focuses on two core technology areas: oncolytic viruses and Chimeric Antigen Receptor (CAR) T-cell therapies. Elicera's key asset is the proprietary iTANK (Immuno-Oncology Targeting and Killing) technology platform, a universal solution designed to enhance the efficacy of any CAR T-cell therapy by enabling a multi-targeted immune attack, particularly against solid tumors. The company's pipeline includes four drug candidates, with its oncolytic virus (ELC-100) and CAR T-cell therapy (ELC-301) in or entering clinical phase I/II trials for neuroendocrine tumors and B-cell lymphoma, respectively.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Elicera Therapeutics AB filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Elicera Therapeutics AB via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2025-03-11 Margareth Jorvid Other Other 21,700 40,145.00 SEK

Peer Companies

Company Country Ticker View
Krka Logo
Develops and sells generic prescription, non-prescription, and animal health products globally.
Slovenia KRKG
KUKJEON PHARMACEUTICAL Co.,Ltd Logo
A chemical solutions provider manufacturing Active Pharmaceutical Ingredients and electronic materials.
South Korea 307750
KWANGDONG PHARMACEUTICAL CO.,LTD Logo
Developing drugs & health goods by integrating oriental and Western medicine.
South Korea 009290
Kyivmedpreparat Logo
A leading pharmaceutical producer of antibacterial, generic, and original medicines in various forms.
Ukraine KMED
KYONGBO PHARMACEUTICAL CO., LTD. Logo
Manufactures APIs and finished drugs, offering global CDMO services from development to production.
South Korea 214390
KYORIN Pharmaceutical Co., Ltd. Logo
Researches, develops, and sells a portfolio of ethical, generic, and OTC medicines.
Japan 4569
Kyowa Kirin Co.,Ltd. Logo
Develops antibody medicines for oncology, nephrology, immunology, and allergy.
Japan 4151
KyungdongPharm Logo
Develops and manufactures Rx/OTC drugs & APIs for cardiology and other chronic conditions.
South Korea 011040
KYUNG NAM PHARM.CO.,LTD. Logo
South Korean maker of OTC medicines, health foods, and cosmetics, known for its Lemona Vitamin C.
South Korea 053950
Labiana S.A. Logo
Pharmaceutical CDMO for animal & human health with its own line of vaccines and generics.
Spain LAB

Talk to a Data Expert

Have a question? We'll get back to you promptly.